Kadri ÖZER, Özlem ÇOLAK, Yüksel KANKAYA, Uğur KOÇER, Hande AKDENİZ

İHMAL EDİLMİŞ VE DEV BOYUTLARA ULAŞMIŞ DERMATOFİBROSARKOMA PROTUBERANS OLGULARI

Dermatofibrosarkoma protuberans (DFSP), düşük metastaz oranı olan ve yüksek rekürrens oranına sahip cildin dermal tabakasından kaynaklanan lokal agresif bir tümördür. Bu çalışmada literatürde çok nadir görülebilen büyüklükte iki olgu raporlanmaktadır. Her iki olguda da geniş lokal eksizyon yapıldı. Özellikle DFSP fibrosarkomatöz varyantı çok daha titizlikle değerlendirilmesi gereken bir neoplazmdır. Malignensi oranı bu alt tipte çok keskin bir şekilde yükselmekte, iyi prognoz kötüleşmektedir. DFSP, her klinisyenin cilt ile aynı renkte olan ve ağrısız büyüme gösteren plak veya nodüller durumunda düşünmesi gereken bir ön tanı olmalıdır

DERMATOFIBROSARCOMA PROTUBERANS CASES WHICH NEGLECTED AND REACHED GIANT SIZES

Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive tumor that originated from the dermal layer of the skin with a low rate of metastasis and high recurrence rate. In this study, two cases with the size of which was seen very rarely in the literature are reported. In both cases, wide local excision was performed. In particular, DFSP fibrosarcomatous variant is a neoplasm that much more needs to be rigorously evaluated. Malignancy rate increases very sharply at this subtype, the good prognosis is worse. DFSP should be a preliminary diagnosis for all clinicians in case of painless growing skin plaques or nodules which are the same color with the skin

PDF

___

1)Porcaro-Salles JM, Soares JM a, Sousa AA, Pinheiro DL, Reis DCF. Giant dermatofibrosarcoma protuberans: a case report of a surgical reconstruction and patient rehabilitation challenge. J Oral Maxillofac Surg. 2012; 70: 2013–6.
2)Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartín O. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol. 2013; 30: 13–28.
3)Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007; 56: 968–73.
4)Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, et al. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000; 88: 2711–20.
5)Bogucki B, Neuhaus I, Hurst E a. Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg. 2012; 38: 537–51.
6)Liang CA, Jambusaria-Pahlajani A, Karia PS, Elenitsas R, Zhang PD, Schmults CD. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014 Apr 19.
7)Kurlander DE, Martires KJ, Chen Y, Barnholtz-Sloan JS, Bordeaux JS. Risk of subsequent primary malignancies after dermatofibrosarcoma protuberans diagnosis: a national study. J Am Acad Dermatol. 2013; 68: 790–6.
8)Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86: 585–90.
9)McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005; 23: 866–73.
10)Labropoulos S V, Razis ED. Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics. 2007; 1: 347–53.